• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    5/31/24 8:06:22 AM ET
    $ADAP
    $BGXX
    $BNOX
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ADAP alert in real time by email

    Gainers

    • Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 69.6% to $0.77 during Friday's pre-market session. The company's market cap stands at $14.5 million.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) shares moved upwards by 40.59% to $1.42. The market value of their outstanding shares is at $362.8 million.
    • Bionomics (NASDAQ:BNOX) shares moved upwards by 29.56% to $1.28. The market value of their outstanding shares is at $13.6 million.
    • Innovative Eyewear (NASDAQ:LUCY) shares moved upwards by 27.84% to $1.01. The market value of their outstanding shares is at $17.6 million.
    • Xtant Medical Hldgs (AMEX:XTNT) stock moved upwards by 20.97% to $0.9. The market value of their outstanding shares is at $117.3 million.
    • Bright Green (NASDAQ:BGXX) shares increased by 18.16% to $0.26. The company's market cap stands at $50.1 million.

    Losers

    • Summit Therapeutics (NASDAQ:SMMT) stock decreased by 17.9% to $8.97 during Friday's pre-market session. The company's market cap stands at $6.2 billion.
    • Genfit (NASDAQ:GNFT) stock declined by 11.15% to $5.26. The market value of their outstanding shares is at $262.2 million.
    • Pulse Biosciences (NASDAQ:PLSE) stock decreased by 10.79% to $10.75. The company's market cap stands at $593.6 million.
    • Sonoma Pharmaceuticals (NASDAQ:SNOA) stock fell 10.25% to $0.18. The company's market cap stands at $2.8 million.
    • Veeva Systems (NYSE:VEEV) shares declined by 9.11% to $176.5. The company's market cap stands at $28.5 billion. As per the press release, Q1 earnings came out yesterday.
    • OneMedNet (NASDAQ:ONMD) stock declined by 8.43% to $2.39. The company's market cap stands at $57.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAP
    $BGXX
    $BNOX
    $GNFT

    CompanyDatePrice TargetRatingAnalyst
    Veeva Systems Inc.
    $VEEV
    2/17/2026$205.00Underweight → Equal-Weight
    Morgan Stanley
    Pulse Biosciences Inc
    $PLSE
    1/30/2026$25.00Outperform
    Mizuho
    Veeva Systems Inc.
    $VEEV
    1/13/2026$215.00Sell
    Goldman
    Veeva Systems Inc.
    $VEEV
    1/8/2026Hold → Buy
    Truist
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Veeva Systems Inc.
    $VEEV
    12/12/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    Veeva Systems Inc.
    $VEEV
    11/13/2025$300.00Market Perform
    BMO Capital Markets
    More analyst ratings

    $ADAP
    $BGXX
    $BNOX
    $GNFT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Executive Officer Gross Harrison R. bought $2,400 worth of shares (1,500 units at $1.60), increasing direct ownership by 14% to 12,233 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/12/26 5:00:39 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    $ADAP
    $BGXX
    $BNOX
    $GNFT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Veeva Systems upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Veeva Systems from Underweight to Equal-Weight and set a new price target of $205.00

    2/17/26 8:05:30 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    Mizuho initiated coverage on Pulse Biosciences with a new price target

    Mizuho initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $25.00

    1/30/26 6:44:12 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Goldman resumed coverage on Veeva Systems with a new price target

    Goldman resumed coverage of Veeva Systems with a rating of Sell and set a new price target of $215.00

    1/13/26 9:18:31 AM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    $ADAP
    $BGXX
    $BNOX
    $GNFT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on February 18, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to two new employees to purchase, in aggregate, up to 19,000 shares of Company common stock. The Company's i

    2/20/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference

    Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming 46th Annual TD Cowen Healthcare Conference in Boston. Pulse Biosciences' Management is scheduled to present on Wednesday, March 4, 2026, at 1:10 pm ET. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intent

    2/20/26 7:00:00 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025. Recent Business Highlights Endocardial Catheter AF Ablation Highlighted 100% procedural success, or freedom from atrial fibrillation (AF), at 6 months and 96% procedural success at one year, of evaluable patients, following treatments with the nPulse Cardiac Catheter System in the first-in-human feasibility study which was presented as late-breaking data at the 31st Annual AF Symposium Meeting. Receiv

    2/19/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $ADAP
    $BGXX
    $BNOX
    $GNFT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Schallenberger Mark A. covered exercise/tax liability with 7,709 shares, decreasing direct ownership by 1% to 663,157 units (SEC Form 4)

    4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    2/18/26 4:36:56 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Commercial Officer Danahy Kevin Patrick exercised 60,000 shares at a strike of $1.53 and sold $1,410,600 worth of shares (60,000 units at $23.51) (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/17/26 8:47:42 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Danahy Kevin Patrick exercised 60,000 shares at a strike of $1.53 and sold $1,403,400 worth of shares (60,000 units at $23.39) (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/11/26 7:46:34 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $ADAP
    $BGXX
    $BNOX
    $GNFT
    SEC Filings

    View All

    Pulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    2/19/26 4:28:11 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by Pulse Biosciences Inc

    S-3 - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    2/19/26 4:22:58 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Pulse Biosciences Inc

    S-8 - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    2/19/26 4:19:44 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $ADAP
    $BGXX
    $BNOX
    $GNFT
    Leadership Updates

    Live Leadership Updates

    View All

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Innovative Eyewear, Inc. Announces Exciting New Features for the Lucyd ChatGPT App

    MIAMI, May 29, 2025 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ:LUCY, LUCYW)), the manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Eddie Bauer® and Nautica® brands, is pleased to announce a powerful new update to the Company's Lucyd app for iOS and Android. The Lucyd app was the first to enable voice access to ChatGPT in smart eyewear, and the Company believes these latest enhancements further advance its market position as a leader in smart eyewear.   Below are the new updates: App Shopping. Both the iOS and

    5/29/25 8:00:00 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Adaptimmune Reports Q1 Financial Results and Provides Business Update

    TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in Q1 2025Instituting 2025 Tecelra full year sales guidance of $35-$45 millionLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026Adaptimmune had Total Liquidity1 of $60 million as of March 31, 2025; call at 8 a.m. EDT today Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reported financial results and provided a business update for the first quarter ended March

    5/13/25 7:30:00 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $BGXX
    $BNOX
    $GNFT
    Financials

    Live finance-specific insights

    View All

    Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025. Recent Business Highlights Endocardial Catheter AF Ablation Highlighted 100% procedural success, or freedom from atrial fibrillation (AF), at 6 months and 96% procedural success at one year, of evaluable patients, following treatments with the nPulse Cardiac Catheter System in the first-in-human feasibility study which was presented as late-breaking data at the 31st Annual AF Symposium Meeting. Receiv

    2/19/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

    Conference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, phy

    2/17/26 5:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veeva to Release Fiscal 2026 Fourth Quarter and Full Year Results on March 4, 2026

    PLEASANTON, Calif., Feb. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) will announce financial results for its fourth quarter and full fiscal year, which ended January 31, 2026, after market close on March 4, 2026. Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET) to discuss its financial results. Veeva will post prepared remarks to its investor relations website at ir.veeva.com at approximately 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available on the website following the live event. Event: Veeva Systems' Fiscal 2026 Fourth Quarter and Full Year Results Conference Call Date: Wednesday, March 4, 2026 Time: 2:00 p.m. PT (5:00 p.m. ET) Co

    2/11/26 4:05:00 PM ET
    $VEEV
    Computer Software: Prepackaged Software
    Technology

    $ADAP
    $BGXX
    $BNOX
    $GNFT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bionomics Limited

    SC 13G - BIONOMICS LIMITED/FI (0001191070) (Subject)

    11/14/24 3:25:19 PM ET
    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bionomics Limited

    SC 13G/A - BIONOMICS LIMITED/FI (0001191070) (Subject)

    11/14/24 9:03:54 AM ET
    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Innovative Eyewear Inc.

    SC 13G/A - Innovative Eyewear Inc (0001808377) (Subject)

    11/13/24 11:18:48 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care